By admin | Published:
February 27, 2008
Timothy Illidge
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
February 26, 2008
Bart Barlogie
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
BART BARLOGIE, University of Arkansas, Little Rock
A treatment known as “total therapy” could cure many patients with multiple myeloma, conference-goers have just heard. The targeted drugs thalidomide and bortezomib, coupled with tandem autologous transplants, are used by Arkansas-based Bart Barlogie. In Paris he told Peter Goodwin about their success.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
February 26, 2008
Martin Dreyling
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
February 26, 2008
John Gribben
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in News, Oncology | Tagged drug, failure, hematologic, leukemia, london, malignancy, reports, rituximab, symposium, therapies |
By admin | Published:
February 25, 2008
Kenneth Anderson
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston
Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel therapies which are turning prospects around for this malignancy. So said Kenneth Anderson at the European meeting in Paris. He explained to Peter Goodwin how a number of molecular and other therapies are changing the prospects for this disease.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
